REVIVEPEPTIDES
0

What the trials behind the approved IGF-1 showed in children who cannot make it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Chernausek, Backeljauw and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2007 the pooled long-term experience of recombinant IGF-1 in 76 children with severe primary IGF-1 deficiency, most with growth hormone receptor defects, followed for up to twelve years. Height velocity, very low before treatment, roughly doubled in the first year and remained above baseline thereafter, though the catch-up was less complete than growth hormone achieves in growth hormone deficiency. Hypoglycaemia was the commonest adverse effect, with lymphoid tissue enlargement, intracranial hypertension and coarsening of facial features also recorded. The data supported the approval and define what the native hormone does when it is the missing piece.

The population

Children with Laron syndrome and related conditions: high growth hormone, very low IGF-1, severe short stature, no response to growth hormone because the receptor does not work. The only way to supply the signal is to supply IGF-1 itself. The group is rare, which is why the trials were small and pooled across sites and years.

This is the population for which the approved product exists.

What was found

Growth velocity increased most in the first year and declined toward a sustained moderate gain. Final heights, where reached, remained below the population range but above untreated expectation. Hypoglycaemia, because IGF-1 acts on glucose, was managed by giving the hormone with meals. Tonsillar and adenoidal growth, from IGF-1 action on lymphoid tissue, sometimes required surgery. These effects reflect the biology of the hormone acting without the binding-protein buffer that a normal person has.

The analogue LR3, which also escapes the buffer, would be expected to show the same effects more strongly, which the rat studies suggested.

Why it is here

Because it is the human evidence for what IGF-1 does as a drug, in the one condition where it is the right drug. It describes no use of the pack, which is not that product.

IGF-1 LR3 is supplied by REVIVE LAB UAE for laboratory research use only, with identity and purity documented for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
IGF-1 LR3 Pack1 mgAED 650In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The population?

Children with Laron syndrome and related conditions: high growth hormone, very low IGF-1, severe short stature, no response to growth hormone because the receptor does not work. The only way to supply the signal is to supply IGF-1 itself. The group is rare, which is why the trials were small and pooled across sites and years.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

IGF-1 LR3 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

→ IGF-1 LR3 Pack — 1 mg → Mecasermin, and what LR3 is not → IGF1 gene deletion in humans

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.